- Home
- H vs ICLR Comparison
H vs ICLR Comparison
Compare H & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | H | ICLR |
|---|---|---|
| Founded | 1957 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 14.3B |
| IPO Year | 2009 | 1998 |
Fundamental Metrics
Financial Performance| Metric | H | ICLR |
|---|---|---|
| Price | $165.47 | $187.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 14 |
| Target Price | $164.00 | ★ $202.38 |
| AVG Volume (30 Days) | 743.4K | ★ 802.7K |
| Earning Date | 02-12-2026 | 02-18-2026 |
| Dividend Yield | ★ 0.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.47 |
| Revenue | $3,339,000,000.00 | ★ $8,102,602,000.00 |
| Revenue This Year | $120.45 | N/A |
| Revenue Next Year | $4.12 | $0.66 |
| P/E Ratio | ★ N/A | $24.38 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $102.43 | $125.10 |
| 52 Week High | $168.10 | $228.29 |
Technical Indicators
Market Signals| Indicator | H | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 60.07 |
| Support Level | $158.91 | $180.48 |
| Resistance Level | $166.87 | $184.93 |
| Average True Range (ATR) | 3.95 | 5.29 |
| MACD | -0.40 | -0.01 |
| Stochastic Oscillator | 73.24 | 79.84 |
Price Performance
Historical ComparisonAbout H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 40 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.